MA39750B1 - Derivatives of aza-indol-acetic acid and their use as modulators of prostaglandin receptors d2 - Google Patents
Derivatives of aza-indol-acetic acid and their use as modulators of prostaglandin receptors d2Info
- Publication number
- MA39750B1 MA39750B1 MA39750A MA39750A MA39750B1 MA 39750 B1 MA39750 B1 MA 39750B1 MA 39750 A MA39750 A MA 39750A MA 39750 A MA39750 A MA 39750A MA 39750 B1 MA39750 B1 MA 39750B1
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- indol
- aza
- acetic acid
- derivatives
- Prior art date
Links
- 102000015433 Prostaglandin Receptors Human genes 0.000 title abstract 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des dérivés d'acide aza-indol-acétique de formule (i), dans laquelle r1 et r2 sont tels que définis dans la description, et leur utilisation comme modulateurs des récepteurs des prostaglandines, plus particulièrement comme modulateurs des récepteurs de la prostaglandine d2, dans le traitement de divers troubles et maladies à médiation par des prostaglandines, ainsi que des compositions pharmaceutiques contenant lesdits composés et des procédés pour leur préparationThe present invention relates to aza-indol-acetic acid derivatives of formula (i), wherein r1 and r2 are as defined in the description, and their use as modulators of prostaglandin receptors, more particularly as modulators of prostaglandin d2, in the treatment of various disorders and diseases mediated by prostaglandins, as well as pharmaceutical compositions containing said compounds and methods for their preparation
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2014059883 | 2014-03-17 | ||
| EP15714030.2A EP3119779B1 (en) | 2014-03-17 | 2015-03-16 | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| PCT/IB2015/051895 WO2015140684A1 (en) | 2014-03-17 | 2015-03-16 | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39750A MA39750A (en) | 2017-01-25 |
| MA39750B1 true MA39750B1 (en) | 2018-12-31 |
Family
ID=52808086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39750A MA39750B1 (en) | 2014-03-17 | 2015-03-16 | Derivatives of aza-indol-acetic acid and their use as modulators of prostaglandin receptors d2 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9879006B2 (en) |
| EP (1) | EP3119779B1 (en) |
| JP (1) | JP6152489B2 (en) |
| KR (1) | KR101864060B1 (en) |
| CN (1) | CN106103435B (en) |
| AR (1) | AR099767A1 (en) |
| AU (1) | AU2015233029B2 (en) |
| BR (1) | BR112016021471B1 (en) |
| CA (1) | CA2939892C (en) |
| CL (1) | CL2016002321A1 (en) |
| CY (1) | CY1120744T1 (en) |
| DK (1) | DK3119779T3 (en) |
| EA (1) | EA030159B1 (en) |
| ES (1) | ES2687279T3 (en) |
| HR (1) | HRP20181555T1 (en) |
| HU (1) | HUE039614T2 (en) |
| IL (1) | IL247705B (en) |
| LT (1) | LT3119779T (en) |
| MA (1) | MA39750B1 (en) |
| MX (2) | MX384987B (en) |
| MY (1) | MY179356A (en) |
| PE (1) | PE20161177A1 (en) |
| PH (1) | PH12016501764B1 (en) |
| PL (1) | PL3119779T3 (en) |
| PT (1) | PT3119779T (en) |
| RS (1) | RS57867B1 (en) |
| SG (1) | SG11201607708RA (en) |
| SI (1) | SI3119779T1 (en) |
| TW (1) | TWI649321B (en) |
| UA (1) | UA117780C2 (en) |
| WO (1) | WO2015140684A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101864060B1 (en) | 2014-03-17 | 2018-06-01 | 이도르시아 파마슈티컬스 리미티드 | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| AU2015233046A1 (en) | 2014-03-18 | 2016-11-03 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
| KR20180053345A (en) * | 2015-09-15 | 2018-05-21 | 이도르시아 파마슈티컬스 리미티드 | Crystalline form |
| KR102480088B1 (en) * | 2016-03-17 | 2022-12-23 | 삼성디스플레이 주식회사 | Quantum dot light emitting device |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808608A (en) | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
| DE3631824A1 (en) | 1986-02-21 | 1988-03-31 | Bayer Ag | CYCLOALKANO (1.2-B) INDOL-SULFONAMIDE |
| GB8924392D0 (en) | 1989-10-30 | 1989-12-20 | Bayer Ag | Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| US20030055077A1 (en) | 2000-04-12 | 2003-03-20 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| JP4279561B2 (en) | 2001-05-23 | 2009-06-17 | メルク フロスト カナダ リミテツド | Dihydropyrrolo [1,2-a] indole and tetrahydropyrido [1,2-a] -indole derivatives as prostaglandin D2 receptor antagonists |
| AU2002361430B2 (en) | 2001-12-14 | 2007-09-13 | Zentaris Gmbh | Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR) |
| US6837970B2 (en) | 2001-12-18 | 2005-01-04 | Kimberly-Clark Worldwide, Inc. | Wood pulp fiber morphology modifications through thermal drying |
| AR038136A1 (en) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS |
| SE0200411D0 (en) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (en) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP1505061A4 (en) | 2002-05-16 | 2007-08-22 | Shionogi & Co | Compound exhibiting pgd 2 receptor antagonism |
| JPWO2003097042A1 (en) | 2002-05-16 | 2005-09-15 | 塩野義製薬株式会社 | PGD2 receptor antagonist |
| GB2388540A (en) | 2002-05-17 | 2003-11-19 | Bayer Ag | New use of Ramatroban |
| SE0201635D0 (en) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (en) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| WO2004039807A1 (en) | 2002-10-30 | 2004-05-13 | Merck Frosst Canada & Co. | Pyridopyrrolizine and pyridoindolizine derivatives |
| US20060089353A1 (en) | 2003-03-06 | 2006-04-27 | Maki Iwahashi | Indole derivative compounds and drugs containing the compounds as the active ingredient |
| WO2004103970A1 (en) | 2003-05-20 | 2004-12-02 | Merck Frosst Canada Ltd. | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists |
| SE0301569D0 (en) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| WO2004111047A2 (en) | 2003-06-12 | 2004-12-23 | Merck Frosst Canada Ltd. | Cycloalkanepyrrolopyridines as dp receptor antagonists |
| SE0302232D0 (en) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| WO2005033099A2 (en) | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| US20070232681A1 (en) | 2003-10-14 | 2007-10-04 | Oxagen Limited | Compounds Having Crth2 Antagonist Activity |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB2407318A (en) | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (en) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| DK1718649T3 (en) | 2004-01-31 | 2009-08-24 | Actimis Pharmaceuticals Inc | Imidazo [1,2-c] pyrimidinyleddikesyrederivater |
| BRPI0508579A (en) | 2004-03-11 | 2007-08-14 | Actelion Pharmaceuticals Ltd | compound, pharmaceutical composition, and use of a compound |
| KR100808742B1 (en) | 2004-03-11 | 2008-02-29 | 액테리온 파마슈티칼 리미티드 | Tetrahydropyridoindole derivatives |
| US20050234030A1 (en) | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| GB0412914D0 (en) | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| AU2005286717A1 (en) | 2004-09-21 | 2006-03-30 | Wyeth | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof |
| KR20070089908A (en) | 2004-09-21 | 2007-09-04 | 아더시스 인코포레이티드 | Indole Acetic Acid and its Uses Showing CrtH2 Receptor Antagonism |
| GB0427381D0 (en) | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
| AU2005320964B2 (en) | 2004-12-27 | 2011-12-15 | Actelion Pharmaceuticals Ltd. | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
| DOP2006000016A (en) | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-PHENYL-INDOLES AS ANTAGONISTS OF THE PROSTAGLANDIN RECEPTOR D2. |
| GB2422830A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| GB2422829A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| NZ560513A (en) | 2005-02-25 | 2010-07-30 | Ono Pharmaceutical Co | Indole compound and use thereof |
| GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| RU2478639C2 (en) | 2005-05-24 | 2013-04-10 | Лаборатуар Сероно С.А. | Tricyclic spiro-derivatives as crth2 modulators |
| GB0512944D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Indolizine compounds |
| WO2007010965A1 (en) | 2005-07-22 | 2007-01-25 | Shionogi & Co., Ltd. | Azaindole derivative having pgd2 receptor antagonistic activity |
| EP1916245B1 (en) | 2005-07-22 | 2011-10-26 | Shionogi & Co., Ltd. | Indole derivative having pgd2 receptor antagonist activity |
| CA2618550C (en) | 2005-08-12 | 2013-12-17 | Merck Frosst Canada Ltd. | Indole derivatives as crth2 receptor antagonists |
| EP1931632A4 (en) | 2005-08-18 | 2011-05-11 | Microbia Inc | Useful indole compounds |
| JP5147401B2 (en) | 2005-09-06 | 2013-02-20 | 塩野義製薬株式会社 | Indolecarboxylic acid derivatives having PGD2 receptor antagonist activity |
| GB0518783D0 (en) | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
| GB0521275D0 (en) | 2005-10-19 | 2005-11-30 | Argenta Discovery Ltd | 3-Aminoindole compounds |
| GB0525144D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525143D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525141D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525337D0 (en) | 2005-12-13 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0605743D0 (en) | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| JP2009538289A (en) | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | Biaryl or heteroaryl substituted indoles |
| GB0611695D0 (en) | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
| US7999119B2 (en) | 2006-07-22 | 2011-08-16 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| MX2009000830A (en) | 2006-07-25 | 2009-02-03 | Sanofi Aventis | 2-phenyl-indoles as prostaglandin d2 receptor antagonists. |
| NZ574705A (en) | 2006-08-07 | 2011-12-22 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
| EA200970590A1 (en) | 2006-12-21 | 2009-12-30 | Арджента Дискавери Лимитед | CRTH2 ANTAGONISTS |
| GB0625842D0 (en) | 2006-12-22 | 2007-02-07 | Argenta Discovery Ltd | Indolizine derivatives |
| CA2681409A1 (en) | 2007-03-21 | 2008-09-25 | Argenta Oral Therapeutics Limited | Indolizine acetic acid derivatives as crth2 antagonists |
| GB0719485D0 (en) | 2007-10-05 | 2007-11-14 | Argenta Discovery Ltd | Compounds |
| GB0719521D0 (en) | 2007-10-05 | 2007-11-14 | Argenta Discovery Ltd | Compounds |
| KR101442663B1 (en) | 2007-10-10 | 2014-09-22 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | Heterocyclic Compounds as CRTH2 Receptor Antagonists |
| WO2009061676A2 (en) | 2007-11-06 | 2009-05-14 | Amira Pharmaceuticals, Inc. | Antagonists of pgd2 receptors |
| GB0722216D0 (en) | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| GB0722203D0 (en) | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| PT2250161E (en) | 2008-01-18 | 2014-01-21 | Atopix Therapeutics Ltd | Compounds having crth2 antagonist activity |
| US20110060026A1 (en) | 2008-01-18 | 2011-03-10 | George Hynd | Indoles Active on CRTH2 Receptor |
| WO2009093026A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| JP2011088826A (en) | 2008-01-31 | 2011-05-06 | Astellas Pharma Inc | Aromatic carboxylic acid compound |
| US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
| US8501959B2 (en) | 2008-06-24 | 2013-08-06 | Panmira Pharmaceuticals, Llc | Cycloalkane[B]indole antagonists of prostaglandin D2 receptors |
| EP2307382B1 (en) | 2008-07-15 | 2011-12-21 | F. Hoffmann-La Roche AG | Aminotetrahydroindazoloacetic acids |
| WO2010006944A1 (en) | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Aminotetrahydroindazoloacetic acids |
| US8546422B2 (en) | 2008-09-22 | 2013-10-01 | Merck Canada Inc. | Azaindole derivatives as CRTH2 receptor antagonists |
| WO2010031183A1 (en) | 2008-09-22 | 2010-03-25 | Merck Frosst Canada Ltd. | Indole derivatives as crth2 receptor antagonists |
| US8637541B2 (en) | 2008-09-22 | 2014-01-28 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
| US20110312945A1 (en) | 2008-10-01 | 2011-12-22 | James Jia | Crth2 modulators |
| GB2465062B (en) * | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| WO2010085820A2 (en) | 2009-01-26 | 2010-07-29 | Amira Pharmaceuticals, Inc. | Tricyclic compounds as antagonists of prostaglandin d2 receptors |
| US8394819B2 (en) | 2009-02-24 | 2013-03-12 | Merck Sharp & Dohme Corp. | Indole derivatives as CRTH2 receptor antagonists |
| WO2010142934A1 (en) | 2009-06-12 | 2010-12-16 | Pulmagen Therapeutics (Asthma) Limited | Indole derivatives as ligands of crth2 receptors |
| US20120115895A1 (en) | 2009-07-15 | 2012-05-10 | Merck Serono S.A. | Tricyclic indole-derived spiro derivatives as crth2 modulators |
| EP2480225A4 (en) * | 2009-07-31 | 2013-05-01 | Panmira Pharmaceuticals Llc | Dermal formulations of dp2 receptor antagonists |
| WO2011055270A1 (en) | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
| EP2558447B1 (en) * | 2010-03-22 | 2014-09-17 | Actelion Pharmaceuticals Ltd. | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| US20110311483A1 (en) | 2010-03-30 | 2011-12-22 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| MX338516B (en) | 2011-04-14 | 2016-04-20 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators. |
| CN103450218B (en) | 2012-05-29 | 2015-12-23 | 山东亨利医药科技有限责任公司 | As the indoles three also ring derivatives of CRTH2 receptor antagonist |
| KR101864060B1 (en) * | 2014-03-17 | 2018-06-01 | 이도르시아 파마슈티컬스 리미티드 | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| AU2015233046A1 (en) | 2014-03-18 | 2016-11-03 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
| KR20180053345A (en) | 2015-09-15 | 2018-05-21 | 이도르시아 파마슈티컬스 리미티드 | Crystalline form |
-
2015
- 2015-03-16 KR KR1020167028863A patent/KR101864060B1/en not_active Expired - Fee Related
- 2015-03-16 PH PH1/2016/501764A patent/PH12016501764B1/en unknown
- 2015-03-16 UA UAA201610385A patent/UA117780C2/en unknown
- 2015-03-16 MX MX2019011265A patent/MX384987B/en unknown
- 2015-03-16 MA MA39750A patent/MA39750B1/en unknown
- 2015-03-16 JP JP2016558110A patent/JP6152489B2/en not_active Expired - Fee Related
- 2015-03-16 US US15/125,018 patent/US9879006B2/en active Active
- 2015-03-16 RS RS20181191A patent/RS57867B1/en unknown
- 2015-03-16 AR ARP150100789A patent/AR099767A1/en unknown
- 2015-03-16 WO PCT/IB2015/051895 patent/WO2015140684A1/en not_active Ceased
- 2015-03-16 HU HUE15714030A patent/HUE039614T2/en unknown
- 2015-03-16 PE PE2016001617A patent/PE20161177A1/en unknown
- 2015-03-16 TW TW104108362A patent/TWI649321B/en not_active IP Right Cessation
- 2015-03-16 CN CN201580013857.XA patent/CN106103435B/en not_active Expired - Fee Related
- 2015-03-16 HR HRP20181555TT patent/HRP20181555T1/en unknown
- 2015-03-16 EP EP15714030.2A patent/EP3119779B1/en active Active
- 2015-03-16 ES ES15714030.2T patent/ES2687279T3/en active Active
- 2015-03-16 LT LTEP15714030.2T patent/LT3119779T/en unknown
- 2015-03-16 BR BR112016021471-4A patent/BR112016021471B1/en not_active IP Right Cessation
- 2015-03-16 MY MYPI2016703359A patent/MY179356A/en unknown
- 2015-03-16 PL PL15714030T patent/PL3119779T3/en unknown
- 2015-03-16 PT PT15714030T patent/PT3119779T/en unknown
- 2015-03-16 MX MX2016011901A patent/MX368179B/en active IP Right Grant
- 2015-03-16 SG SG11201607708RA patent/SG11201607708RA/en unknown
- 2015-03-16 EA EA201691855A patent/EA030159B1/en not_active IP Right Cessation
- 2015-03-16 CA CA2939892A patent/CA2939892C/en active Active
- 2015-03-16 AU AU2015233029A patent/AU2015233029B2/en not_active Ceased
- 2015-03-16 SI SI201530381T patent/SI3119779T1/en unknown
- 2015-03-16 DK DK15714030.2T patent/DK3119779T3/en active
-
2016
- 2016-09-08 IL IL247705A patent/IL247705B/en active IP Right Grant
- 2016-09-15 CL CL2016002321A patent/CL2016002321A1/en unknown
-
2017
- 2017-12-14 US US15/842,357 patent/US10301309B2/en active Active
-
2018
- 2018-10-08 CY CY181101039T patent/CY1120744T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37762B1 (en) | N-aryltriazole compounds used as antagonists of lpar | |
| MA37764A1 (en) | N-alkyltriazole compounds used as antagonists of lpar | |
| MA35576B1 (en) | New compounds | |
| WO2019035863A8 (en) | Pyruvate kinase activators for use in treating blood disorders | |
| MA35342B1 (en) | Piperidinyl compounds useful as inhibitors of tankyrase | |
| MA42678B1 (en) | NEW SUBSTITUTED NUCLEOSIDE ANALOGS WITH BICYCLIC AROMATIC CYCLE 6-6 FOR USE AS PRMT5 INHIBITORS | |
| MA43979B1 (en) | 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders | |
| MA39783A (en) | USEFUL QUINOXALINE DERIVATIVES AS FGFR KINASE MODULATORS | |
| WO2019007696A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| MA40111A1 (en) | Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein | |
| MA41562B1 (en) | 4-hydroxy-3- (heteroaryl) pyridine-2-one agonists for use in the treatment of cardiovascular disorders | |
| MA38483A1 (en) | Inhibitors of ido | |
| MA37888A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| MA35444B1 (en) | Ep1 receptor ligands | |
| MA42397B1 (en) | Substituted 4-azaindoles and their use as modulators of the glun2b receptor | |
| MA37765A1 (en) | Substituted pyrazole compounds used as lpar antagonists | |
| MA46229B1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| MA49127B1 (en) | N-substituted indole derivatives | |
| MA39750B1 (en) | Derivatives of aza-indol-acetic acid and their use as modulators of prostaglandin receptors d2 | |
| MA40149A1 (en) | Substituted 4'-vinyl nucleoside derivatives useful as inhibitors of respiratory syncytial virus rna replication | |
| MA38410B1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MA38679B1 (en) | Cxcr7 receiver modulators | |
| MA43913A (en) | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M1 RECEPTOR | |
| MA39253A1 (en) | Substituted bicyclic heteroaryl compounds used as rxr agonists | |
| MA44965A (en) | PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES OF THEM AS AOC3 INHIBITORS |